A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies

CONCLUSION: Our findings highlight the substantially low rate of seroprotection in patients with hematological malignancies with a wide range of rates among disease subgroups and different treatments; further highlighting the fact that booster doses might be acquired for these patients to improve immunity against SARS-CoV-2.PMID:35843148 | PMC:PMC9273573 | DOI:10.1016/j.intimp.2022.109046
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research